Literature DB >> 32225140

Cooling or Warming the Esophagus to Reduce Esophageal Injury During Left Atrial Ablation in the Treatment of Atrial Fibrillation.

Jason Zagrodzky1, Mark M Gallagher2, Lisa W M Leung2, Tiffany Sharkoski3, Pasquale Santangeli4, Cory Tschabrunn4, Jose M Guerra5, Bieito Campos5, John MacGregor6, Jamal Hayat2, Brad Clark7, Alex Mazur8, Marcel Feher9, Martin Arnold9, Mark Metzl10, Jose Nazari10, Erik Kulstad11.   

Abstract

Ablation of the left atrium using either radiofrequency (RF) or cryothermal energy is an effective treatment for atrial fibrillation (AF) and is the most frequent type of cardiac ablation procedure performed. Although generally safe, collateral injury to surrounding structures, particularly the esophagus, remains a concern. Cooling or warming the esophagus to counteract the heat from RF ablation, or the cold from cryoablation, is a method that is used to reduce thermal esophageal injury, and there are increasing data to support this approach. This protocol describes the use of a commercially available esophageal temperature management device to cool or warm the esophagus to reduce esophageal injury during left atrial ablation. The temperature management device is powered by standard water-blanket heat exchangers, and is shaped like a standard orogastric tube placed for gastric suctioning and decompression. Water circulates through the device in a closed-loop circuit, transferring heat across the silicone walls of the device, through the esophageal wall. Placement of the device is analogous to the placement of a typical orogastric tube, and temperature is adjusted via the external heat-exchanger console.

Entities:  

Year:  2020        PMID: 32225140     DOI: 10.3791/60733

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  1 in total

1.  Randomized comparison of oesophageal protection with a temperature control device: results of the IMPACT study.

Authors:  Lisa W M Leung; Abhay Bajpai; Zia Zuberi; Anthony Li; Mark Norman; Riyaz A Kaba; Zaki Akhtar; Banu Evranos; Hanney Gonna; Idris Harding; Manav Sohal; Nawaf Al-Subaie; John Louis-Auguste; Jamal Hayat; Mark M Gallagher
Journal:  Europace       Date:  2021-02-05       Impact factor: 5.214

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.